S. Di Cosimo
Hebron University
CancerSurgeryOncologyMetastatic breast cancerEribulinChemotherapyAnthracyclineLapatinibBreast surgeryCardiotoxicityNeoadjuvant therapyChemotherapy regimenTrastuzumabPrimary tumorPopulationGynecologyBreast cancerClinical trialMedicinePI3K/AKT/mTOR pathway
Publications 87
#1P NuciforoH-Index: 6
#1Paolo NuciforoH-Index: 41
Last. Jens HuoberH-Index: 26
view all 19 authors...
#1E. La Rocca (University of Milan)H-Index: 1
Last. Maria De SantisH-Index: 32
view all 13 authors...
AIM: To assess the impact of age, comorbidities and endocrine therapy (ET) in older breast cancer (BC) patients treated with hypofractionated radiotherapy (Hypo-RT). METHODS: From June 2009 to December 2017, we enrolled in this study 735 ER-positive BC patients (stage pT1-T2, pNx-1, M0 and age ≥ 65 years) receiving hypo-RT and followed them until September 2019. Baseline comorbidities included in the hypertension-augmented Charlson Comorbidity Index were retrospectively retrieved. Logistic regre...
1 CitationsSource
#1S. Di CosimoH-Index: 15
#2Marco SilvestriH-Index: 3
Last. M. G. DaidoneH-Index: 2
view all 9 authors...
#1M.C. De SantisH-Index: 1
#1M. De SantisH-Index: 13
Last. S. Di CosimoH-Index: 15
view all 16 authors...
Background Primary tumor characteristics, which are readily available to all clinicians, may aid in selecting the optimal adjuvant therapy for patients with breast cancer (BC). Herein, we investigated the relationship between tumor size, hormone receptor and HER2 status, Ki67 and age with axillary lymph node metastases (ALNM) in early-BC patients.
#1E. La RoccaH-Index: 1
#2Laura LozzaH-Index: 18
Last. M. De SantisH-Index: 13
view all 11 authors...
To report acute toxicities in breast cancer (BC) patients (pts) recruited in a prospective trial and treated with accelerated partial-breast irradiation (APBI) using Volumetric Modulated Arc Therapy (VMAT) delivered with a hypofractionated schedule. From March 2014 to June 2019, pts with early-stage BC (Stage I), who underwent breast conservative surgery (BCS), were recruited in a prospective study started at the National Cancer Institute of Milan. Pts received APBI with a hypofractionated sched...
#1S. Di CosimoH-Index: 15
#2Valentina AppiertoH-Index: 15
Last. Maria Grazia DaidoneH-Index: 59
view all 12 authors...
1 CitationsSource
#2S. Di CosimoH-Index: 15
Last. J. CortésH-Index: 14
view all 16 authors...
Abstract Background EMILIA, TH3RESA, and KAMILLA phase III trials showed that T-DM1 is highly active and safe as single agent in HER2[+] MBC. T-DM1 and NPLD may be safely combined to increase antitumor effect compared to each agent alone. The aim of this trial is to determine the dose-limiting toxicity (DLT) and maximum tolerate dose (MTD) of T-DM1 plus NPLD in HER2[+] MBC. Methods A 3 + 3 dose escalation design was used. Main selection criteria were: (1) Women with HER2[+] MBC ≥ 18 years (yrs);...
#1S. Di CosimoH-Index: 15
#2Annalisa TramaH-Index: 26
Last. Matteo Franchi (University of Milano-Bicocca)H-Index: 11
view all 8 authors...
Abstract Background Clinical trials, focusing on selected pts, may have underestimated toxicities in cases with advanced age and co-morbidities, that are common in RW practice. Furthermore, clinical trials do not provide extended F/U. Thus, we assessed acute and long-term SCEs after adjuvant T in a large/unselected BC pt population. Methods Using healthcare administrative database, ie clinical discharge records and drug prescriptions of the Lombardy region (Italy), we selected pts newly diagnose...
#1J. CortésH-Index: 14
#2V. CalvoH-Index: 2
Last. J. BaselgaH-Index: 31
view all 18 authors...
1 CitationsSource
Close Researchers